{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:20:38Z","timestamp":1763828438737,"version":"3.45.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Standard induction chemotherapy for acute myeloid leukemia (AML) using cytarabine combined with anthracyclines (epirubicin\/IA or daunorubicin\/DA) is effective but associated with severe adverse effects. The HAG regimen (low-dose homoharringtonine, cytarabine, G-CSF), known for lower toxicity, shows promise in adult AML, but its application in pediatric AML remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study investigated the feasibility and efficacy of the HAG regimen in pediatric AML. Twenty-four newly diagnosed pediatric AML patients (excluding M3 subtype) were enrolled between August 2021 and November 2022. Patients received the HAG regimen as induction therapy. Drug sensitivity testing was performed to evaluate in vitro efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After the first induction cycle with HAG, the overall complete remission (CR) rate was 75% (18\/24). Patients classified as ELN favorable and intermediate-risk achieved a 100% CR rate. The 1-year overall survival (OS) rate was 83.3% \u00b1 7.6%, and the 3-year OS rate was 75.0% \u00b1 8.8%. The 1-year event-free survival (EFS) rate was 75.0% \u00b1 8.8%, and the 3-year EFS rate was 66.1% \u00b1 9.8%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The HAG regimen demonstrates high efficacy and holds great promise for pediatric AML. It achieves survival outcomes comparable to more intensive regimens while offering the significant advantage of reduced toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf340","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:17:50Z","timestamp":1763558270000},"source":"Crossref","is-referenced-by-count":0,"title":["In vitro drug sensitivity and clinical efficacy of the HAG regimen in pediatric AML"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-1154","authenticated-orcid":false,"given":"Diying","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Pediatric Hematology-Oncology Center, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiling","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Pediatric Hematology-Oncology Center, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Pediatric Hematology-Oncology Center, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Pediatric Hematology-Oncology Center, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3349-8789","authenticated-orcid":false,"given":"Jingying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Pediatric Hematology-Oncology Center, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025112211170935700_oyaf340-B1","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"2025112211170935700_oyaf340-B2","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3390\/ph16111614","article-title":"A review of childhood acute myeloid leukemia: diagnosis and novel treatment","volume":"16","author":"Tseng","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025112211170935700_oyaf340-B3","first-page":"10","article-title":"Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study","volume":"9","author":"Yamada","year":"1995","journal-title":"Leukemia"},{"key":"2025112211170935700_oyaf340-B4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-4-46","article-title":"A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Wei","year":"2011","journal-title":"J Hematol Oncol"},{"key":"2025112211170935700_oyaf340-B5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med"},{"key":"2025112211170935700_oyaf340-B6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/JCO.1985.3.5.617","article-title":"Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia","volume":"3","author":"Warrell","year":"1985","journal-title":"J Clin Oncol"},{"key":"2025112211170935700_oyaf340-B7","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase","volume":"86","author":"O\u2019Brien","year":"1995","journal-title":"Blood"},{"key":"2025112211170935700_oyaf340-B8","first-page":"698","article-title":"[Comparison of curative effects of HAG and CAG regimens for patients with AML and medium\/High-Risk MDS]","volume":"24","author":"Zhu","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2025112211170935700_oyaf340-B9","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.18632\/oncotarget.6211","article-title":"HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia","volume":"7","author":"Hu","year":"2016","journal-title":"Oncotarget"},{"key":"2025112211170935700_oyaf340-B10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2025112211170935700_oyaf340-B11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"2025112211170935700_oyaf340-B12","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"key":"2025112211170935700_oyaf340-B13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.clinre.2020.01.003","article-title":"In vitro high-throughput drug sensitivity screening with patient-derived primary cells as a guide for clinical practice in hepatocellular carcinoma-A retrospective evaluation","volume":"44","author":"Li","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025112211170935700_oyaf340-B14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"Singh","year":"2015","journal-title":"J Pharmacol Pharmacother"},{"key":"2025112211170935700_oyaf340-B15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0040-4039(01)97839-6","article-title":"Structures of harringtonine, isoharringtonine, and homoharringtonine","author":"Powell","year":"1970","journal-title":"Tetrahedron Lett"},{"key":"2025112211170935700_oyaf340-B16","first-page":"485","article-title":"[Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1]","volume":"41","author":"Shen","year":"2012","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"2025112211170935700_oyaf340-B17","first-page":"487","article-title":"Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells","volume":"118","author":"Mai","year":"2005","journal-title":"Chin Med J (Engl)"},{"key":"2025112211170935700_oyaf340-B18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-8722-2-32","article-title":"A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China","volume":"2","author":"Wang","year":"2009","journal-title":"J Hematol Oncol"},{"key":"2025112211170935700_oyaf340-B19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00258117","article-title":"Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells","volume":"14","author":"Takemura","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025112211170935700_oyaf340-B20","first-page":"2031","article-title":"Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro","volume":"50","author":"Zhou","year":"1990","journal-title":"Cancer Res"},{"key":"2025112211170935700_oyaf340-B21","first-page":"1191","article-title":"Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation","volume":"7","author":"Te Boekhorst","year":"1993","journal-title":"Leukemia"},{"key":"2025112211170935700_oyaf340-B22","doi-asserted-by":"crossref","first-page":"e0164238","DOI":"10.1371\/journal.pone.0164238","article-title":"HAG (homoharringtonine, cytarabine, G-CSF) regimen for the treatment of acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis with 2,314 participants","volume":"11","author":"Xie","year":"2016","journal-title":"PLoS One"},{"key":"2025112211170935700_oyaf340-B23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00277-022-05047-8","article-title":"Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT","volume":"102","author":"Sun","year":"2023","journal-title":"Ann Hematol"},{"key":"2025112211170935700_oyaf340-B24","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/cancers12102766","article-title":"Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia","volume":"12","author":"Mohanty","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025112211170935700_oyaf340-B25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12887-024-04954-1","article-title":"Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Pediatr"},{"key":"2025112211170935700_oyaf340-B26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428194.2014.910774","article-title":"Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia","volume":"56","author":"Chen","year":"2015","journal-title":"Leuk \u00adLymphoma"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf340\/65415625\/oyaf340.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf340\/65415625\/oyaf340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf340\/65415625\/oyaf340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:17:18Z","timestamp":1763828238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf340\/8332239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf340","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"oyaf340"}}